Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Agenus announces Phase II results from gastroesophageal cancer therapy

Summary by Clinical Trials Arena
Agenus has reported results from a Phase II trial, evaluating the combination of BOT, BAL, and agenT-797 alongside ramucirumab and paclitaxel, in advanced PD-1 refractory gastroesophageal adenocarcinoma patients.The post Agenus announces Phase II results from gastroesophageal cancer therapy appeared first on Clinical Trials Arena.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

Verdict HospitalVerdict Hospital
Reposted by
Clinical Trials ArenaClinical Trials Arena

Agenus announces Phase II results from gastroesophageal cancer therapy

Agenus has reported results from a Phase II trial, evaluating the combination of BOT, BAL, and agenT-797 alongside ramucirumab and paclitaxel, in advanced PD-1 refractory gastroesophageal adenocarcinoma patients.The post Agenus announces Phase II results from gastroesophageal cancer therapy appeared first on Hospital Management.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Clinical Trials Arena broke the news on Monday, April 20, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal